Holen Sie sich die Stockscreener-App
78.06
2.35%
-1.8478
Schlusskurs vom Vortag:
$79.91
Offen:
$79.77
24-Stunden-Volumen:
821.08K
Relative Volume:
0.34
Marktkapitalisierung:
$14.95B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-32.39
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
+2.33%
1M Leistung:
+2.14%
6M Leistung:
+68.94%
1J Leistung:
+110.39%
1-Tages-Spanne:
$77.89
$80.58
1-Wochen-Bereich:
$73.77
$81.33
52-Wochen-Spanne:
$28.32
$81.33
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
78.03 | 15.31B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.64 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.00 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.53 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Wells Fargo remains a buy on BridgeBio Pharma (BBIO) - MSN
Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO) - Yahoo Finance UK
Emerald Mutual Fund Advisers Trust Lowers Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma stock hits all-time high at 79.88 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighStill a Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 79.88 USD - Investing.com
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC - MarketBeat
How BridgeBio’s (BBIO) Convertible Notes and Attruby Uptake Have Changed Its Investment Story - simplywall.st
BridgeBio Pharma Issues New Convertible Notes and Repurchases Stock - TipRanks
Bridgebio Pharma Inc Issues $632.5 Million Convertible Senior Notes Due 2033 - TradingView — Track All Markets
Avoiding Lag: Real-Time Signals in (BBIO) Movement - Stock Traders Daily
Wells Fargo Raises Price Target on BBIO, Maintains Overweight Ra - GuruFocus
Wells Fargo & Company Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $88.00 - MarketBeat
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Finviz
Analysts remain positive on BridgeBio Pharma, Inc. (BBIO) after strong 2025 results - MSN
Mizuho Markets Americas LLC Has $7.29 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio prices $550 million convertible notes at 0.75% interest rate By Investing.com - Investing.com Nigeria
Latham & Watkins Advises on BridgeBio Pharma’s US$550 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next - TechStock²
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Lobbying Update: $60,000 of BRIDGEBIO PHARMA lobbying was just disclosed - Quiver Quantitative
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected - Intellectia AI
BridgeBio Pharma prices $550M convertible bond offering - MSN
BridgeBio Pharma Prices $550 Million Convertible Notes Offering - Intellectia AI
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BridgeBio Pharma prices $550 million convertible notes offering By Investing.com - Investing.com Canada
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033 - Nasdaq
BridgeBio prices $550 million convertible notes at 0.75% interest rate - Investing.com
BridgeBio Pharma, Inc. Announces Pricing of $550 Million Convertible Senior Notes to Enhance Capital Structure and Extend Debt Maturity - Quiver Quantitative
BridgeBio Prices Offering of $550 Million Convertible - GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownHere's What Happened - MarketBeat
BridgeBio’s US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO - Yahoo Finance
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress - Yahoo Finance
BridgeBio plans $550 million convertible notes offering to refinance debt By Investing.com - Investing.com Nigeria
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio plans $550 million convertible notes offering to refinance debt - Investing.com
BridgeBio Pharma, Inc. Announces Private Offering of $550 Million Convertible Senior Notes to Strengthen Balance Sheet and Extend Debt Maturity - Quiver Quantitative
BridgeBio Pharma Plans Offering of Senior Notes due 2033 - marketscreener.com
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio continues long term debt management strategy and announces proposed offering of convertible senior notes - marketscreener.com
Biotech BridgeBio reworks $550M in new notes and cash for buybacks - Stock Titan
Ideas Watch: What is the PEG ratio of BridgeBio Pharma IncPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
BridgeBio Pharma (BBIO) Gets a Buy from Raymond James - The Globe and Mail
BridgeBio Pharma stock hits all-time high at 78.69 USD By Investing.com - Investing.com Nigeria
Aug Reactions: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Catalysts & Long-Term Growth Plans - baoquankhu1.vn
Will BridgeBio Pharma Inc stock deliver strong dividend growth2025 Sector Review & Breakout Confirmation Alerts - moha.gov.vn
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighShould You Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.69 USD - Investing.com
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.07%
1.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):